Grow Your Pharma Business Digitally
Weekly News Recap #Phispers
Stock Recap #PipelineProspector
Virtual Booth
Contact Supplier
Check COS databaseCheck USDMF database
Contact UsPharmaScopic.com
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tegafur,Gimeracil,Oteracil
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Positive EMA Opinion for the Use of Teysuno in Metastatic Colorectal Cancer
Details : Based on the positive opinion from EMA, Teysuno (Tegafur) an oral fluoropyrimidine will be indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.
Product Name : Teysuno
Product Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2022
Highest Development Status : Approved
Stock Recap#PipelineProspector
Data Compilation#PharmaFlow